fei li

Dr. fei li


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2019 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
FLfei li
fei li
XLXinji Li
Xinji Li
LQLi Qiao
Li Qiao
WLWen Liu
Wen Liu
CXChengshan Xu
Chengshan Xu
XWXiaogang Wang
Xiaogang Wang
Melanoma is one of the most common skin malignancies. Both microRNAs and long non-coding RNAs (lncRNAs) have critical roles in the progression of cancers, including melanoma. However, the underlying molecular mechanism has not been fully characterized. We demonstrated that miR-34a is negatively correlated with MALAT1 in melanoma cells and tumor specimens. Interestingly, MALAT1, which contains functional sequence-specific miR-34a-binding sites, regulates miR-34a stability in melanoma cells and in vivo. Importantly, MALAT1 was significantly enriched in the Ago2 complex, but not when the MALAT1-binding site of miR-34a was mutated. Furthermore, MALAT1 could be shown to regulate c-Myc and Met expression by functioning as a miR-34a sponge. Our results reveal an unexpected mode of action for MALAT1 as an important regulator of miR-34a.

1 August 2025 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
FLfei li
fei li
XLXinji Li
Xinji Li
TNTianhui Niu
Tianhui Niu
XLXiaoxin Li
Xiaoxin Li
LGLing Guan
Ling Guan
CSChengyu Sui
Chengyu Sui
Background: Cutaneous melanoma (CM) exhibits considerable heterogeneity, and the immune status of patients can serve as a prognostic indicator. The increasing significance of immune-related markers in cancer prognosis provides clinicians with valuable tools for risk stratification and management decisions. The objective of this study was to develop a predictive model for assessing the risk of CM based on novel subtypes delineated according to immune-related genes. Methods: This study included a cohort from The Cancer Genome Atlas (TCGA). Immune-related genes were carefully selected, and a comprehensive analysis was performed to characterize the molecular alterations and clinical implications linked to these genes. From this, an immune-related risk scoring system aimed at predicting the survival outcomes of patients diagnosed with CM was developed. Results: In this study, using an unsupervised consensus clustering algorithm, the study identified two subtypes—Cluster 1 (C1) and Cluster 2 (C2)—within the TCGA melanoma (MEL) cohort based on 1,959 immune-related genes. Survival analysis indicated that C1 was linked to poorer overall survival (OS) as compared to C2. We found significant correlations between these subtypes and clinical variables including tumor-node-metastasis (TNM) classification, new tumor events, and radiation therapy. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed that 161 genes upregulated in C1 were associated with tyrosine metabolism, melanogenesis, and the p53 signaling pathway, while downregulated genes in C1 were linked to hematopoietic cell lineage, cytokine-cytokine receptor interactions, and cell adhesion molecules. Immune-related genes in CM were optimized and assessed using univariate Cox regression and a protein-protein interaction (PPI) network, with 20 genes being identified, including CXCL10, CCL5, CXCR4, CXCR3, IL10, CCR5, CCR7, STAT1, TNF, CD4, CD8A, ITGB2, FCGR3A, ITGAM, PTPRC, CD19, LCK, B2M, TYROBP, and IFNG. From these, four key prognostic markers (CXCL10, IL10, B2M, and IFNG) were selected via a least absolute shrinkage and selection operator (LASSO) regression penalty approach and multivariate Cox analyses. For the prediction of the 1-, 3-, and 5-year survival rates, the immune-related risk score yielded area under the curve (AUC) values of 0.671, 0.667, and 0.676, respectively. Conclusions: CM was divided into two subtypes based on immune gene expression, with the C1 subtype associated with poor prognosis. A prognostic risk model was developed using these classifications to predict patient outcomes.

Verified
Journal Article
Open access
PDF file
ZYZihao Yu
Zihao Yu
FLfei li
fei li
YQYing Quan
Ying Quan
WHWeijian HU
Weijian HU
PZPing Zhang
Ping Zhang
XXXin Xie
Xin Xie
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous malignancy characterized by the proliferation of skin-homing CD4+ T cells and profound immune dysregulation within the tumor microenvironment (TME). This review synthesizes evidence on chemokine–receptor networks that govern malignant T-cell trafficking among blood, skin, and lymph nodes, the formation of immunosuppressive niches, and clinically actionable biomarker candidates. Among the best-supported axes, CCL17/CCL22–CCR4 and CCL27/CCL28–CCR10 mediate skin tropism, CCL19/CCL21–CCR7 contributes to lymph node homing, and CXCL12–CXCR4 supports skin trafficking and is associated with disease progression. In contrast, CCR2/CCR5/CCR6/CCR8-centered circuits and CXCR3/CXCR5 pathways are emerging regulators of myeloid recruitment, regulatory T-cell accumulation, and context-dependent immune activation. Therapeutically, agents targeting chemokine pathways, most notably the CCR4 monoclonal antibody Mogamulizumab, have demonstrated clinical efficacy, while emerging inhibitors of CCR6, CCR5, and CXCR4 offer promising avenues for intervention. We further highlight how recent single-cell and other high-dimensional omics studies refine cell-type–specific chemokine sources and receptor expression, enabling more precise mapping of chemokine-driven intercellular communication programs in CTCL TME remodeling and better prioritization of therapeutic targets and biomarkers.